Trial Profile
Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 10 Aug 2017 New trial record